Novo Nordisk researchers nominated for Europe's top innovation prize

Novo NordiskA team of researchers from Novo Nordisk is nominated for Europe's top innovation prize, Inventor of the Year 2008 Award, that will be presented at a ceremony in Ljubljana, Slovenia, on 6 May by the European Patent Office and the European Commission.

Prizes will be awarded in four categories: industry, small- and medium-sized enterprises/research institutes, non-European countries and lifetime achievement. Novo Nordisk is nominated in the 'industry' category, competing against French aviation company Airbus and German automaker Audi.

The invention for which the Novo Nordisk researchers are nominated concerns Levemir® (insulin detemir), a long-acting modern insulin that covers the body's basal insulin need and which today is used by more than one million people with diabetes. They have been nominated for "significantly improving the safety and quality of life of diabetes patients with a new insulin derivative for once-daily administration".

"The patent describes a technology for prolonging the duration of action of insulin. The invention is pioneering a new generation of modified human peptide hormones, because the technology can be applied more broadly to optimise the therapeutic value of proteins, including insulin and GLP-1," explains Svend Havelund, one of the inventors.

This year's award ceremony will be held alongside the European Patent Forum 2008, 'Inventing a cleaner future', in Ljubljana. The awards will be presented by Danilo Türk, the president of the Republic of Slovenia, and Alison Brimelow, the president for the European Patent Office.

The prize recognises inventors and innovations that have made a significant and lasting contribution to technical development in Europe and beyond and thus have strengthened Europe's economic position. All the nominated projects were patented by the European Patent Office between 1993 and 2002.

The team of Novo Nordisk researchers are Svend Havelund, John Broberg Halstrom, Ib Jonassen, Asser Sloth Andersen and Jan Markussen.

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Probiotics can protect the skeletons of older wome…

For the first time in the world, researchers at the University of Gothenburg, Sweden, have demonstrated that probiotics, dietary supplements with health-promoting bacteri...

Alzheimer's breakthrough: Brain metals that may dr…

Alzheimer's disease could be better treated, thanks to a breakthrough discovery of the properties of the metals in the brain involved in the progression of the neurodegen...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

In mice, stem cells seem to work in fighting obesi…

Obesity is an increasing global health problem associated with several comorbidities and a high risk of mortality. A wide spectrum of interventions has been proposed for ...

FDA takes steps to foster greater efficiency in bi…

Today, the agency withdrew the draft guidance, "Statistical Approaches to Evaluate Analytical Similarity," issued in September 2017. The draft guidance, if finalized as w...

Research shows how a moderate dose of alcohol prot…

For at least 20 years, research has shown that for many people, moderate consumption of alcohol can protect the heart, but the reason for this is poorly understood. A stu...

'Kiss of death' cancer

It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negativ...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...